Description: PepGen, Inc. is a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Deliver Oligonucleotide, or EDO, platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, we are generating a pipeline of oligonucleotide therapeutic candidates that target the root cause of serious diseases.
Home Page: www.pepgen.com
PEPG Technical Analysis
245 Main Street
Cambridge,
MA
02142
United States
Phone:
781-797-0979
Officers
| Name | Title |
|---|---|
| Dr. James G. McArthur Ph.D. | Pres, CEO, Treasurer, Sec. & Director |
| Ms. Caroline Godfrey Ph.D. | Founder & Scientific Advisory Board Member |
| Mr. Noel Donnelly M.B.A. | Chief Financial Officer |
| Dr. Jaya Goyal Ph.D. | Exec. VP of Research & Preclinical Devel. |
| Dr. Michael Gait | Founder & Scientific Advisory Board Member |
| Dr. Sonia Bracegirdle DPHIL | Sr. VP of Strategy & Operations |
| Ms. Jennifer Cormier | Sr. VP of Clinical Operations |
| Dr. Michelle L. Mellion M.D. | Sr. VP & Head of Clinical Devel. |
| Mr. Niels Svenstrup Ph.D. | Sr. VP of Chemistry, Manufacturing & Control |
| Mr. Kyle Breidenstine | VP of Fin. & Controller |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.6645 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2022-05-06 |
| Fiscal Year End: | December |
| Full Time Employees: | 40 |